Revolution Medicines (RVMD) officer exercises options, sells 37,450 shares under 10b5-1 plan

Rhea-AI Filing Summary

Revolution Medicines, Inc. officer Anthony Mancini exercised options and sold shares of common stock. He exercised options for 37,450 shares of common stock at an exercise price of $33.6200 per share and received 37,450 shares.

On the same date, he sold a total of 37,450 shares in multiple open-market transactions at prices ranging from $93.2230 to $97.2071, pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. After these transactions, he directly holds 54,800 shares of common stock, which the footnotes state includes 54,400 restricted stock units.

Insights

Equity compensation analyst

Exercise-and-sell under a 10b5-1 plan, with sizable shares retained.

Anthony Mancini exercised stock options for 37,450 shares at an exercise price of $33.6200 and sold the same number of shares in open-market trades between $93.2230 and $97.2071. This is a classic exercise-and-sell pattern.

The filing specifies that these trades were made under a Rule 10b5-1 trading plan adopted on December 24, 2025, indicating they were pre-planned rather than opportunistic. Following the transactions, Mancini still directly holds 54,800 shares of common stock, including 54,400 restricted stock units, so he retains a meaningful equity stake.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Anthony

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/25/2026		M(1)		37,450	A	$33.62	91,850(2)	D
Common Stock	03/25/2026		S(1)		1,800	D	$93.223(3)	90,050(2)	D
Common Stock	03/25/2026		S(1)		3,128	D	$94.1561(4)	86,922(2)	D
Common Stock	03/25/2026		S(1)		21,086	D	$95.4859(5)	65,836(2)	D
Common Stock	03/25/2026		S(1)		11,036	D	$96.4299(6)	54,800(2)	D
Common Stock	03/25/2026		S(1)		400	D	$97.2071(7)	54,400(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$33.62	03/25/2026		M(1)			37,450	(8)	03/31/2035	Common Stock	37,450	$0	112,350	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025.

2. Includes 54,400 Restricted Stock Units.

3. This transaction was executed in multiple trades at prices ranging from $92.69 to $93.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $93.75 to $94.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $95.00 to $95.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $96.00 to $96.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $97.12 to $97.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Chief Global Commercialization Officer

	/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Anthony Mancini do in this Revolution Medicines (RVMD) Form 4?

Anthony Mancini exercised options for 37,450 Revolution Medicines shares at $33.6200 and sold 37,450 common shares in open-market trades between $93.2230 and $97.2071. After these transactions, he directly holds 54,800 common shares, including 54,400 restricted stock units.

How many Revolution Medicines shares did Anthony Mancini sell in this filing?

He sold a total of 37,450 Revolution Medicines common shares. The sales occurred in multiple open-market transactions at prices ranging from $93.2230 to $97.2071, matching the number of shares acquired through the same-day stock option exercise.

At what price did Anthony Mancini exercise his Revolution Medicines stock options?

He exercised stock options for 37,450 underlying Revolution Medicines common shares at an exercise price of $33.6200 per share. These exercised options converted into common stock, which was then sold in multiple open-market transactions at significantly higher prices.

Were Anthony Mancini’s Revolution Medicines share sales pre-planned under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. Such plans pre-schedule trades, indicating the timing of these sales was arranged in advance rather than decided spontaneously.

How many Revolution Medicines shares does Anthony Mancini hold after these transactions?

After the reported exercise and sales, he directly holds 54,800 Revolution Medicines common shares. A footnote clarifies that this total includes 54,400 restricted stock units, which are share-based awards that typically vest over time subject to continued service.

What type of equity award did Anthony Mancini exercise at Revolution Medicines?

He exercised a stock option covering 37,450 Revolution Medicines common shares. The option had an exercise price of $33.6200 per share and an expiration date of March 31, 2035, and vests monthly over four years from an April 1, 2025 vesting commencement date.